Jun 9, 2026 · 7 min
GSK buys Nuvalent for billions while climate woes hit Vail Resorts
Nuvalent Deal; JM Smucker Reports; Vail Resorts Drops
This episode illustrates how corporate giants are navigating growth through high-stakes acquisitions, pricing power in inflationary times, and the unpredictable impact of weather on leisure.
- 1GSK is investing 10.6 billion dollars to acquire Nuvalent and secure advanced lung cancer therapies.
- 2JM Smucker successfully leveraged price hikes to deliver strong quarterly profits despite lower sales volumes.
- 3Vail Resorts cut its financial guidance following historically poor winter snowfall in the western United States.
The brief
GSK is making a major moves in oncology, launching a massive 10.6 billion dollar acquisition of biotech firm Nuvalent to lock down promising new lung cancer treatments.
Meanwhile, consumer goods giant JM Smucker is proving that pricing power can offset declining sales volumes, posting strong fourth-quarter profits by raising prices on everyday goods.
On the leisure side, Vail Resorts is facing a stark reminder of climate vulnerability, lowering its financial guidance after historically poor snow conditions in the western US.
Listen to the full episode and explore every guest, topic, and moment on PodLume.